



## Press Release

### **STADA recovers top-selling product and will distribute the Parkinson's medication in Germany and Scandinavia in the future**

Bad Vilbel, June 15, 2018 – STADA Arzneimittel AG continues to advance its strategic reorientation. On June 1<sup>st</sup>, STADAPHARM GmbH, the subsidiary focused on specialty pharmaceuticals, will take over the sale of APO-go in Germany from Grünenthal GmbH. Beginning October 1st, STADA Nordic ApS will do the same in Sweden, Norway, Denmark, and Finland. APO-go is a medication for the treatment of Parkinson's' Disease. In fiscal year 2017, with sales of 68.2 million euros, it was STADA's best-selling product.

"In the future, the central nervous system (CNS) will be one of the focuses of our specialty pharmaceuticals area, along with oncology, diabetes, and ophthalmology. In light of this, distributing our current best-selling specialty pharmaceutical ourselves in as many countries as possible is a very important step," explained STADA-CEO Dr. Claudio Albrecht. "In addition to biosimilars, the internationalization of successful products is one of the business areas with the greatest potential for growth for STADA," said Albrecht further.

APO-go, with the active ingredient Apomorphine, is located within STADA subsidiary Britannia Pharmaceuticals Ltd, and joined the STADA portfolio when Britannia was acquired in 2007. It is sold by companies and partners of the STADA group under the names APO-go, MOVAPO, and APOKYN in a total of 30 countries, including the USA, Canada, Australia, New Zealand, as well as all European core markets.

#### **About STADA Arzneimittel AG**

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, non-prescription OTC products and specialty pharmaceuticals, biosimilars in particular. Worldwide, STADA is represented in about 30 countries with roughly 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2017, STADA achieved adjusted Group sales of Euro 2,255.3 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of

Executive Board: Dr. Claudio Albrecht (CEO) / Mark Keatley

Supervisory Board Chairman: Dr. Günter von Au



Euro 433.9 million and adjusted net income of Euro 195.6 million. As of December 31, 2017, STADA employed 10,176 people worldwide.

**Additional information for journalists:**

STADA Arzneimittel AG / Media Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany /

Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: [press@stada.de](mailto:press@stada.de)

Or visit us on the Internet at [www.stada.com](http://www.stada.com)

Executive Board: Dr. Claudio Albrecht (CEO) / Mark Keatley

Supervisory Board Chairman: Dr. Günter von Au